Initial Treatment Approach for Juvenile Idiopathic Arthritis

Diagnostic and Treatment Considerations

• The American College of Rheumatology recommends scheduled NSAIDs as initial therapy for oligoarticular JIA, with a conditional recommendation 1, 2
• The American College of Rheumatology conditionally recommends intraarticular glucocorticoid injections as part of initial therapy for oligoarticular JIA 1, 2
• Triamcinolone hexacetonide is strongly recommended as the preferred agent for intraarticular injection over other steroid types by the American College of Rheumatology 2
• Oral glucocorticoids are conditionally recommended against as initial therapy for oligoarticular JIA by the American College of Rheumatology 1, 2
• Conventional synthetic DMARDs are strongly recommended as second-line therapy for oligoarticular JIA by the American College of Rheumatology 1, 2
• Methotrexate is conditionally recommended as the preferred agent over leflunomide, sulfasalazine, and hydroxychloroquine for oligoarticular JIA by the American College of Rheumatology 2
• Biologic DMARDs are strongly recommended as third-line therapy for oligoarticular JIA after failure of NSAIDs/IAGCs and at least one conventional synthetic DMARD by the American College of Rheumatology 1, 2
• For systemic JIA, NSAIDs are conditionally recommended as initial monotherapy by the American College of Rheumatology 3
• Oral glucocorticoids are conditionally recommended against as initial monotherapy for systemic JIA by the American College of Rheumatology 3
• Conventional synthetic DMARDs are strongly recommended against as initial monotherapy for systemic JIA by the American College of Rheumatology 3
• IL-1 and IL-6 inhibitors are strongly recommended over conventional synthetic DMARDs for inadequate response to NSAIDs and/or glucocorticoids in systemic JIA by the American College of Rheumatology 3
• For enthesitis-related arthritis, NSAIDs are strongly recommended as first-line therapy by the American College of Rheumatology 4
• Physical therapy is conditionally recommended for those with or at risk for functional limitations in enthesitis-related arthritis by the American College of Rheumatology 4
• TNF inhibitors are strongly recommended for sacroiliitis in enthesitis-related arthritis by the American College of Rheumatology 4
• TNF inhibitors are conditionally recommended over methotrexate or sulfasalazine for enthesitis in enthesitis-related arthritis by the American College of Rheumatology 4
• Prolonged oral glucocorticoids as monotherapy should be avoided, and are only recommended for short-term bridging (<3 months) by the American College of Rheumatology 1, 3, 4
• Validated disease activity measures should be used to guide treatment decisions and facilitate treat-to-target approaches by the American College of Rheumatology 1, 2
• Poor prognostic features, such as involvement of ankle, wrist, hip, sacroiliac joint, TMJ, erosive disease, enthesitis, delay in diagnosis, elevated inflammation markers, and symmetric disease, should be considered to guide treatment escalation by the American College of Rheumatology 1, 2

Initial Management of AC Joint Pain in Adolescents

Differential Diagnosis and Initial Management

• The American College of Rheumatology suggests that systemic symptoms, such as fever, multiple joint involvement, and morning stiffness, raise concern for juvenile idiopathic arthritis in adolescents with AC joint pain 5
• Enthesitis-related arthritis should be considered if AC joint involvement is part of broader entheseal inflammation, according to the American College of Rheumatology 6, 7

Initial Management for Inflammatory Arthritis

• Laboratory studies, including CBC with differential, ESR, and CRP, are recommended to assess inflammation in adolescents with suspected inflammatory arthritis, as suggested by the American Academy of Pediatrics 5
• Imaging, including plain radiographs and ultrasound, is recommended to detect effusion and assess for other joint involvement in adolescents with suspected inflammatory arthritis, according to the American College of Radiology 5
• NSAIDs are strongly recommended as first-line therapy for enthesitis, which can involve the AC joint region, as suggested by the American College of Rheumatology 6, 7
• Physical therapy is conditionally recommended for adolescents with enthesitis who have or are at risk for functional limitations, according to the American Physical Therapy Association 6, 7
• Bridging oral glucocorticoids (<3 months) may be considered during initiation of therapy if high disease activity, limited mobility, or significant symptoms are present, as suggested by the American College of Rheumatology 6, 7
• TNF inhibitors are conditionally recommended over methotrexate or sulfasalazine for active enthesitis despite NSAIDs, according to the American College of Rheumatology 6, 7

Critical Pitfalls to Avoid

• The American Academy of Pediatrics recommends that insidious onset AC pain should not be dismissed as simple overuse without ruling out inflammatory arthritis, as early DMARD therapy is crucial for JIA to prevent permanent joint damage 5, 8, 9
• Prolonged oral glucocorticoids should not be used as monotherapy for inflammatory conditions, as they are only for short-term bridging (<3 months), according to the American College of Rheumatology 6, 7

Treatment Approach for Juvenile Idiopathic Arthritis

Initial Assessment and Management

• The American College of Rheumatology recommends starting scheduled NSAIDs immediately as adjunct therapy for children with suspected juvenile idiopathic arthritis, while expediting rheumatology referral 10, 11

Subtype-Specific Treatment Algorithms

• For oligoarticular JIA, the American College of Rheumatology conditionally recommends scheduled NSAIDs and intraarticular glucocorticoid injections as initial therapy, with triamcinolone hexacetonide strongly recommended over triamcinolone acetonide for intraarticular injections 10, 11
• For polyarticular JIA, the American College of Rheumatology recommends NSAIDs as adjunct therapy, and methotrexate should be initiated as first-line disease-modifying therapy without delay, with subcutaneous methotrexate conditionally recommended over oral methotrexate 11
• For systemic JIA, the American College of Rheumatology conditionally recommends NSAIDs and IL-1 and IL-6 inhibitors as initial monotherapy, with conventional synthetic DMARDs strongly recommended against as initial monotherapy 10

Adjunctive Therapies

• The American College of Rheumatology conditionally recommends physical therapy and/or occupational therapy for children who have or are at risk for functional limitations 11

Critical Treatment Principles

• The American College of Rheumatology recommends using validated disease activity measures, such as cJADAS-10, to guide treatment decisions and facilitate treat-to-target approaches, with low disease activity defined as cJADAS-10 ≤2.5 with ≥1 active joint, and moderate/high disease activity defined as cJADAS-10 >2.5 11
• The American College of Rheumatology recommends considering poor prognostic features, such as involvement of ankle, wrist, hip, sacroiliac joint, TMJ, erosive disease, enthesitis, delay in diagnosis, elevated inflammation markers, and symmetric disease, to guide treatment escalation 11

Medication Management

• The American College of Rheumatology recommends an adequate trial of methotrexate for 3 months, but if no or minimal response is observed after 6-8 weeks, changing or adding therapy may be appropriate 11
• The American College of Rheumatology recommends against prolonged oral glucocorticoids as monotherapy and only recommends short-term bridging (<3 months) 11

Adjunctive Role of Celecoxib in Juvenile Idiopathic Arthritis

Treatment Position in the Therapeutic Algorithm

• Celecoxib is recommended only as adjunctive therapy, never as monotherapy, and should not postpone the initiation of disease‑modifying antirheumatic drugs (DMARDs) such as methotrexate. The American College of Rheumatology emphasizes that NSAIDs, including celecoxib, are for symptom control while DMARDs constitute the primary disease‑modifying strategy. Strong recommendation (Level A evidence). 12

• DMARD therapy (particularly methotrexate) is strongly recommended as first‑line treatment for polyarticular JIA, with NSAIDs serving as adjuncts for pain and inflammation control. This reflects the ACR guideline’s hierarchy of interventions, placing DMARDs ahead of NSAIDs in the treatment cascade. Strong recommendation (Level A evidence). 12